BioSpace News Archive

Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month.

Epitomee, a biomedical company that develops unique ingestible therapeutic platforms for deployment of targeted therapies along the GI tract, and Nestlé Health Science, announced today that the patient enrollment for the Epitomee pivotal study has been finalized.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a New Drug Application to the U.S. Food and Drug Administration seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet, plus prednisone, for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.

Lipella Pharmaceuticals Inc. today announced the creation of a Scientific Advisory Board in oral health.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences.

Scholar Rock today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab.

Edgewise Therapeutics, Inc. today announced that management will present at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 am ET.

Ronovo Surgical invited top gynecology and urology surgeons to evaluate the performance of its newly unveiled Carina™ RAS Platform, the first modular robotic-assisted surgery platform developed in China for laparoscopic procedures.

Tachyon Therapeutics, Inc. today announced the closing of a financing that brings the Company’s total equity financing raises to $11.6 million and, together with a recently announced CIRM grant of $7.1 million, brings total funding in the Company to $18.7 million since the Company started operations in 2020.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences.